Update
$ImmunityBio (IBRX.US)$ ImmunityBio Completes ANKTIVA's Post-Approval Enrollment Of The 100th Patient In BCG Unresponsive NMIBC CIS Trial And Reports A Complete Response Rate Of 71% With A Durable Duration Of Response Ranging Up To 54 Months Reported For 82 Patients Published In NEJM
High responder rate associated with a duration of response ranging as long as 54 months in QUILT-3.032 with 100 patients enrolledUpdated data intended to be submitted as part of a European Medicines Agency (EMA) Submission in Q4 2024Complete response data in 100 patients consistent with CR rate of 71% reported for 82 patients published in NEJM
High responder rate associated with a duration of response ranging as long as 54 months in QUILT-3.032 with 100 patients enrolledUpdated data intended to be submitted as part of a European Medicines Agency (EMA) Submission in Q4 2024Complete response data in 100 patients consistent with CR rate of 71% reported for 82 patients published in NEJM
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
